NewcelX Ltd. (NCEL)

NCM · Healthcare · Biotechnology

$3.23 -1.10%

Closing price as of 2026-06-12 · Source: TEK2day Finance

1-Year Price History -3.6% over period

Key Metrics

Market Cap

$17.4M

Shares Outstanding

5.4M

Exchange

NCM

Currency

USD

About NewcelX Ltd.

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.